Compare FLNT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLNT | NRXS |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 78.9M |
| IPO Year | 2009 | 2023 |
| Metric | FLNT | NRXS |
|---|---|---|
| Price | $3.39 | $6.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 220.9K | 114.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,764,000.00 | $3,569,282.00 |
| Revenue This Year | $5.89 | $172.91 |
| Revenue Next Year | $12.62 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.70 | $2.20 |
| 52 Week High | $4.15 | $9.33 |
| Indicator | FLNT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 43.92 |
| Support Level | $2.95 | $6.79 |
| Resistance Level | $3.57 | $7.79 |
| Average True Range (ATR) | 0.30 | 0.37 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 94.57 | 43.75 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).